← Back to patent-cliff list
Mitoxantrone hydrochloride liposome(Institute Of Hematology & Blood Diseases Hospital)
Tier C — Watch / tradeMitoxantrone hydrochloride liposome(Institute Of Hematology & Blood Diseases Hospital)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TOP2, Pim-1, NS3/NS4A
Indications (approved)：Diffuse large B-cell lymphoma, Acute myeloid leukaemia
Regional status
US
-
EU
-
China
Phase II
2024-05-28
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Mitoxantrone hydrochloride liposome(Institute Of Hematology & Blood Diseases Hospital)?
Approved indications include: Diffuse large B-cell lymphoma, Acute myeloid leukaemia.
When does the Mitoxantrone hydrochloride liposome(Institute Of Hematology & Blood Diseases Hospital) patent expire?
No public expiry year is available for Mitoxantrone hydrochloride liposome(Institute Of Hematology & Blood Diseases Hospital) yet; this page updates once verified.
How do I get a quote for Mitoxantrone hydrochloride liposome(Institute Of Hematology & Blood Diseases Hospital) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01